Intellia Therapeutics' stock has risen ahead of an update on its phase 3 Lonvo-Z study. The company has completed enrollment in the global phase 3 HAELO study for hereditary angioedema and is expected to report topline data. The stock's recent gains may be related to positive results from the study, with some outlets suggesting the company's valuation could increase further.